UA76108C2 - Use of therapeutic combination of fatty acids - Google Patents

Use of therapeutic combination of fatty acids Download PDF

Info

Publication number: UA76108C2
Authority: UA; Ukraine
Prior art keywords: epa; fatty acids; day; disease; precursor
Prior art date: 2000-06-29

Application number

UA20021210705A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Laxdale Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-29

Filing date

2001-06-20

Publication date

2006-07-17

2001-06-20 Application filed by Laxdale Ltd filed Critical Laxdale Ltd

2006-07-17 Publication of UA76108C2 publication Critical patent/UA76108C2/uk

Links

235000014113 dietary fatty acids Nutrition 0.000 title claims description 24
229930195729 fatty acid Natural products 0.000 title claims description 24
239000000194 fatty acid Substances 0.000 title claims description 24
150000004665 fatty acids Chemical class 0.000 title claims description 24
230000001225 therapeutic effect Effects 0.000 title description 5
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims abstract description 179
235000021342 arachidonic acid Nutrition 0.000 claims abstract description 89
229940114079 arachidonic acid Drugs 0.000 claims abstract description 89
JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims abstract description 75
235000020673 eicosapentaenoic acid Nutrition 0.000 claims abstract description 74
229960005135 eicosapentaenoic acid Drugs 0.000 claims abstract description 73
JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims abstract description 73
239000002243 precursor Substances 0.000 claims abstract description 18
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 3
239000000203 mixture Substances 0.000 claims description 25
150000003904 phospholipids Chemical class 0.000 claims description 15
208000014644 Brain disease Diseases 0.000 claims description 4
208000024827 Alzheimer disease Diseases 0.000 claims description 3
206010012289 Dementia Diseases 0.000 claims description 3
208000018737 Parkinson disease Diseases 0.000 claims description 3
230000003412 degenerative effect Effects 0.000 claims description 3
125000004494 ethyl ester group Chemical group 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 2
229940126601 medicinal product Drugs 0.000 claims 2
208000015122 neurodegenerative disease Diseases 0.000 claims 2
230000004770 neurodegeneration Effects 0.000 claims 1
HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 abstract description 2
HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 abstract description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
201000010099 disease Diseases 0.000 description 16
230000000694 effects Effects 0.000 description 16
201000000980 schizophrenia Diseases 0.000 description 12
235000004626 essential fatty acids Nutrition 0.000 description 9
239000003921 oil Substances 0.000 description 8
239000002253 acid Substances 0.000 description 7
239000003814 drug Substances 0.000 description 7
230000006872 improvement Effects 0.000 description 7
239000002775 capsule Substances 0.000 description 6
229940079593 drug Drugs 0.000 description 6
210000000170 cell membrane Anatomy 0.000 description 5
230000007423 decrease Effects 0.000 description 5
150000002066 eicosanoids Chemical class 0.000 description 5
238000000034 method Methods 0.000 description 5
235000020660 omega-3 fatty acid Nutrition 0.000 description 5
239000000843 powder Substances 0.000 description 5
108010064785 Phospholipases Proteins 0.000 description 4
102000015439 Phospholipases Human genes 0.000 description 4
150000007513 acids Chemical class 0.000 description 4
210000003743 erythrocyte Anatomy 0.000 description 4
150000002148 esters Chemical class 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
239000000463 material Substances 0.000 description 4
239000012528 membrane Substances 0.000 description 4
239000000902 placebo Substances 0.000 description 4
229940068196 placebo Drugs 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
241000233866 Fungi Species 0.000 description 3
208000022559 Inflammatory bowel disease Diseases 0.000 description 3
150000001408 amides Chemical class 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
210000000748 cardiovascular system Anatomy 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
230000009931 harmful effect Effects 0.000 description 3
230000036541 health Effects 0.000 description 3
238000010348 incorporation Methods 0.000 description 3
208000027866 inflammatory disease Diseases 0.000 description 3
235000020777 polyunsaturated fatty acids Nutrition 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
208000020925 Bipolar disease Diseases 0.000 description 2
206010006895 Cachexia Diseases 0.000 description 2
102000014914 Carrier Proteins Human genes 0.000 description 2
208000032928 Dyslipidaemia Diseases 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
241000282412 Homo Species 0.000 description 2
OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
208000017170 Lipid metabolism disease Diseases 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
241000700605 Viruses Species 0.000 description 2
MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
230000003110 anti-inflammatory effect Effects 0.000 description 2
208000006673 asthma Diseases 0.000 description 2
230000008901 benefit Effects 0.000 description 2
210000000481 breast Anatomy 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
230000008859 change Effects 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
230000037213 diet Effects 0.000 description 2
210000005069 ears Anatomy 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
210000001508 eye Anatomy 0.000 description 2
VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 2
235000020664 gamma-linolenic acid Nutrition 0.000 description 2
VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 2
229960002733 gamolenic acid Drugs 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
125000005456 glyceride group Chemical group 0.000 description 2
210000003128 head Anatomy 0.000 description 2
230000035876 healing Effects 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
208000002551 irritable bowel syndrome Diseases 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
235000020778 linoleic acid Nutrition 0.000 description 2
OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
239000007788 liquid Substances 0.000 description 2
208000019423 liver disease Diseases 0.000 description 2
208000030159 metabolic disease Diseases 0.000 description 2
230000037353 metabolic pathway Effects 0.000 description 2
244000005700 microbiome Species 0.000 description 2
210000000214 mouth Anatomy 0.000 description 2
230000000926 neurological effect Effects 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
229940094443 oxytocics prostaglandins Drugs 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000002265 prevention Effects 0.000 description 2
150000003180 prostaglandins Chemical class 0.000 description 2
210000002307 prostate Anatomy 0.000 description 2
230000001850 reproductive effect Effects 0.000 description 2
208000023504 respiratory system disease Diseases 0.000 description 2
239000007858 starting material Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
230000001732 thrombotic effect Effects 0.000 description 2
210000000515 tooth Anatomy 0.000 description 2
LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
241000195493 Cryptophyta Species 0.000 description 1
235000021298 Dihomo-γ-linolenic acid Nutrition 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000371 Esterases Proteins 0.000 description 1
229920000064 Ethyl eicosapentaenoic acid Polymers 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
229930184725 Lipoxin Natural products 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
244000046052 Phaseolus vulgaris Species 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
208000026723 Urinary tract disease Diseases 0.000 description 1
208000012931 Urologic disease Diseases 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000020661 alpha-linolenic acid Nutrition 0.000 description 1
230000002932 anti-schizophrenic effect Effects 0.000 description 1
230000002785 anti-thrombosis Effects 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
230000008827 biological function Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000000133 brain stem Anatomy 0.000 description 1
229910001424 calcium ion Inorganic materials 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000020411 cell activation Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
150000001840 cholesterol esters Chemical class 0.000 description 1
230000003749 cleanliness Effects 0.000 description 1
230000007012 clinical effect Effects 0.000 description 1
QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
229960004170 clozapine Drugs 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
238000002316 cosmetic surgery Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
208000016097 disease of metabolism Diseases 0.000 description 1
208000037765 diseases and disorders Diseases 0.000 description 1
235000020669 docosahexaenoic acid Nutrition 0.000 description 1
229940090949 docosahexaenoic acid Drugs 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
-1 e.g. Chemical class 0.000 description 1
239000000945 filler Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
150000002617 leukotrienes Chemical class 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
229960004488 linolenic acid Drugs 0.000 description 1
150000002639 lipoxins Chemical class 0.000 description 1
229910003002 lithium salt Inorganic materials 0.000 description 1
159000000002 lithium salts Chemical class 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
239000002674 ointment Substances 0.000 description 1
229940012843 omega-3 fatty acid Drugs 0.000 description 1
239000006014 omega-3 oil Substances 0.000 description 1
230000008520 organization Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
231100000683 possible toxicity Toxicity 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
230000007425 progressive decline Effects 0.000 description 1
239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
238000000746 purification Methods 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
210000004999 sex organ Anatomy 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
150000003595 thromboxanes Chemical class 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
208000014001 urinary system disease Diseases 0.000 description 1
210000001635 urinary tract Anatomy 0.000 description 1
230000002792 vascular Effects 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Communicable Diseases (AREA)
Pulmonology (AREA)
Oncology (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Gastroenterology & Hepatology (AREA)
Ophthalmology & Optometry (AREA)
Virology (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Emergency Medicine (AREA)
Toxicology (AREA)
Dermatology (AREA)
Tropical Medicine & Parasitology (AREA)
Reproductive Health (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

UA20021210705A 2000-06-29 2001-06-20 Use of therapeutic combination of fatty acids UA76108C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0016045.7A GB0016045D0 (en)	2000-06-29	2000-06-29	Therapeutic combinations of fatty acids
PCT/GB2001/002717 WO2002002105A1 (fr)	2000-06-29	2001-06-20	Combinaisons therapeutiques d'acides gras

Publications (1)

Publication Number	Publication Date
UA76108C2 true UA76108C2 (en)	2006-07-17

Family

ID=9894724

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA20021210705A UA76108C2 (en)	2000-06-29	2001-06-20	Use of therapeutic combination of fatty acids

Country Status (32)

Country	Link
US (1)	US6479544B1 (fr)
EP (1)	EP1296670B1 (fr)
JP (1)	JP2004501969A (fr)
KR (1)	KR20030016306A (fr)
CN (1)	CN100469363C (fr)
AT (1)	ATE315388T1 (fr)
AU (2)	AU2001274276B2 (fr)
BR (1)	BR0112073A (fr)
CA (1)	CA2411368C (fr)
CZ (1)	CZ20024173A3 (fr)
DE (1)	DE60116625T2 (fr)
DK (1)	DK1296670T3 (fr)
EE (1)	EE05148B1 (fr)
ES (1)	ES2256250T3 (fr)
GB (1)	GB0016045D0 (fr)
HR (1)	HRP20030035A2 (fr)
HU (1)	HUP0301107A2 (fr)
IL (1)	IL153458A0 (fr)
IS (1)	IS2226B (fr)
MX (1)	MXPA02012689A (fr)
MY (1)	MY117830A (fr)
NO (1)	NO329868B1 (fr)
NZ (1)	NZ522916A (fr)
PL (1)	PL359185A1 (fr)
PT (1)	PT1296670E (fr)
RU (1)	RU2276975C2 (fr)
SK (1)	SK287209B6 (fr)
TW (1)	TWI285549B (fr)
UA (1)	UA76108C2 (fr)
WO (1)	WO2002002105A1 (fr)
YU (1)	YU99602A (fr)
ZA (1)	ZA200300198B (fr)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9901809D0 (en)	1999-01-27	1999-03-17	Scarista Limited	Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
DE10006836B4 (de) *	2000-04-18	2005-03-24	Bitec Gmbh	Verwendung von Omega-3-Fettsäuren und/oder Verbindungen von Omega-3-Fettsäuren
ITMI20010129A1 (it)	2001-01-25	2002-07-25	Pharmacia & Upjohn Spa	Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
JP2003048831A (ja)	2001-08-02	2003-02-21	Suntory Ltd	脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
US20040106584A1 (en)	2002-09-27	2004-06-03	Linda Arterburn	Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation
DE10254584A1 (de) *	2002-11-22	2004-06-09	HORST HEIRLER PROJEKTE für Ernährung, Medizin, Ökologie	Verwendung von mittelkettigen Triglyceriden (MCT) zur ernährungsphysiologischen Optimierung des Fettsäurenspektrums in einem diätetischen Lebensmittel für Diabetiker
GB0311081D0 (en)	2003-05-14	2003-06-18	Btg Internat Limted	Treatment of neurodegenerative conditions
FR2856304B1 (fr) *	2003-06-20	2006-03-03	Natural Product Consulting	Composition pour la prevention des infections du systeme urinaire
EP2324828A1 (fr)	2003-08-18	2011-05-25	BTG International Limited	Traitement de maladies neurodégénératives
US7875291B1 (en)	2003-09-05	2011-01-25	Glu-Pro, Inc.	Composition for managing diabetes, obesity, and hyperlipidemia and associated methods
JP4522075B2 (ja) *	2003-10-29	2010-08-11	サントリーホールディングス株式会社	血管の老化に起因する症状あるいは疾患の予防又は改善作用を有する組成物
US20050249823A1 (en) *	2003-11-04	2005-11-10	Murphy Tanya K	Methods for the prevention or amelioration of neuropsychiatric and related diseases
WO2005046668A1 (fr) *	2003-11-14	2005-05-26	Mochida Pharmaceutical Co., Ltd.	Agent preventif/therapeutique pour traiter les troubles de la parole
DK1543735T3 (en) *	2003-12-20	2015-11-02	Nestec Sa	FOOD COMPOSITION FOR HEALTH CARE
EP1713463A4 (fr) *	2004-01-19	2009-03-18	Martek Biosciences Corp	Dysfonctionnement ou d ficit de reelin et techniques associ es
DK1629850T4 (da)	2004-08-24	2013-07-01	Nutricia Nv	Næringssammensætning indeholdende ufordøjelige oligosaccharider
JP2006083136A (ja) *	2004-09-17	2006-03-30	Suntory Ltd	ストレスに起因する脳機能の低下およびそれに伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP4993852B2 (ja)	2004-09-17	2012-08-08	サントリーホールディングス株式会社	ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
US8431165B2 (en) *	2004-12-13	2013-04-30	Swing Aerobics Licensing, Inc.	Medicament for treatment of cancer and other diseases
US8092839B2 (en) *	2004-12-13	2012-01-10	Swing Aerobics Licensing, Inc.	Medicament for treatment of cancer and other diseases
US20060135610A1 (en) *	2004-12-22	2006-06-22	Bortz Jonathan D	Cardiovascular compositions
GB2421909A (en) *	2004-12-23	2006-07-12	Laxdale Ltd	Pharmaceutical compositions comprising EPA and methods of use
EP1845999A4 (fr) *	2005-01-24	2010-09-22	Pronova Biocare As	Utilisation d'une composition d'acides gras contenant un dha pour la production d'un produit pharmaceutique ou alimentaire destine au traitement de maladies liees a l'amylose
CA2599112C (fr)	2005-02-14	2013-10-22	Suntory Limited	Composition comprenant l'acide dihomo-.gamma.-linolenique (adgl) comme matiere active
GB0504362D0 (en)	2005-03-02	2005-04-06	Btg Int Ltd	Cytokine modulators
JP5967855B2 (ja)	2005-06-30	2016-08-10	サントリーホールディングス株式会社	日中活動量の低下および／又はうつ症状の改善作用を有する組成物
CA2625640A1 (fr) *	2005-12-09	2007-06-21	Drugtech Corporation	Emulsion d'acide gras essentiel intraveineuse
GB0607946D0 (en) *	2006-04-21	2006-05-31	Minster Res The Ltd	Mono and combination therapy
GB0607949D0 (en) *	2006-04-21	2006-05-31	Minster Res The Ltd	Mono and combination therapy
KR101578498B1 (ko)	2006-12-28	2015-12-18	산토리 홀딩스 가부시키가이샤	신경 재생제
US20090011012A1 (en) *	2007-07-06	2009-01-08	Baum Seth J	Fatty acid compositions and methods of use
US8343753B2 (en) *	2007-11-01	2013-01-01	Wake Forest University School Of Medicine	Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
EP3187182B1 (fr)	2008-09-02	2021-03-03	Amarin Pharmaceuticals Ireland Limited	Compositions pharmaceutiques contenant de l'acide eicosapentaénoïque et de l'acide nicotinique, et leurs procédés d'utilisation
RU2505292C2 (ru)	2009-02-10	2014-01-27	Амарин Фармасьютикалз Айрлэнд Лимитед	Способы лечения гипертриглицеридемии
CN107233337A (zh)	2009-04-29	2017-10-10	阿马里纳药物爱尔兰有限公司	含有epa和心血管剂的药物组合物以及使用其的方法
GB0907413D0 (en)	2009-04-29	2009-06-10	Equateq Ltd	Novel methods
MX377553B (es)	2009-04-29	2025-03-10	Amarin Pharma Inc	Composicion farmaceutica estable y metodos de uso de la misma.
BRPI1011883A2 (pt)	2009-06-15	2016-09-13	Amarin Pharma Inc	uso de composições para redução de triglicerídeos sem elevar os níveis de o ldl-c em um paciente sob o tratamento concomitante com estatina
NZ599061A (en)	2009-09-23	2014-05-30	Amarin Pharmaceuticals Ie Ltd	Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
US11712429B2 (en)	2010-11-29	2023-08-01	Amarin Pharmaceuticals Ireland Limited	Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ744990A (en)	2010-11-29	2019-10-25	Amarin Pharmaceuticals Ie Ltd	Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US8865685B2 (en)	2011-06-30	2014-10-21	Johnson & Johnson Vision Care, Inc.	Esters for treatment of ocular inflammatory conditions
US8293790B2 (en)	2011-10-19	2012-10-23	Dignity Sciences Limited	Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
US11291643B2 (en)	2011-11-07	2022-04-05	Amarin Pharmaceuticals Ireland Limited	Methods of treating hypertriglyceridemia
WO2013070735A1 (fr)	2011-11-07	2013-05-16	Amarin Pharmaceuticals Ireland Limited	Méthodes de traitement de l'hypertriglycéridémie
CN107050457A (zh)	2012-01-06	2017-08-18	翁特拉制药公司	游离酸形式的ω‑3多不饱和脂肪酸的富含dpa组合物
EP2800469B1 (fr)	2012-01-06	2021-08-25	Amarin Pharmaceuticals Ireland Limited	Compositions et procédés pour abaisser les taux de crp à haute sensibilité (hs-crp) chez un sujet
KR20150028233A (ko)	2012-05-07	2015-03-13	옴테라 파마슈티칼스, 인크.	스타틴 및 오메가-３ 지방산의 조성물
WO2013192109A1 (fr)	2012-06-17	2013-12-27	Matinas Biopharma, Inc.	Compositions d'acide pentanoïque oméga-3 et leurs procédés d'utilisation
US9603826B2 (en)	2012-06-29	2017-03-28	Amarin Pharmaceuticals Ireland Limited	Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
WO2014074552A2 (fr)	2012-11-06	2014-05-15	Amarin Pharmaceuticals Ireland Limited	Compositions et procédés pour diminuer les triglycérides sans augmenter les taux de ldl-c chez un sujet traité en même temps par la statine
KR20150103009A (ko)	2012-12-06	2015-09-09	마티나스 바이오파마, 인코포레이티드	도코사펜타에노산을 포함하는 조성물의 투여
US10123986B2 (en)	2012-12-24	2018-11-13	Qualitas Health, Ltd.	Eicosapentaenoic acid (EPA) formulations
US9629820B2 (en)	2012-12-24	2017-04-25	Qualitas Health, Ltd.	Eicosapentaenoic acid (EPA) formulations
US9814733B2 (en)	2012-12-31	2017-11-14	A,arin Pharmaceuticals Ireland Limited	Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en)	2012-12-31	2014-07-03	Amarin Pharmaceuticals Ireland Limited	Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US20140221676A1 (en) *	2013-02-06	2014-08-07	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for treating and/or preventing cardiovascular disease
US9452151B2 (en)	2013-02-06	2016-09-27	Amarin Pharmaceuticals Ireland Limited	Methods of reducing apolipoprotein C-III
US9624492B2 (en)	2013-02-13	2017-04-18	Amarin Pharmaceuticals Ireland Limited	Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en)	2013-02-19	2017-05-30	The Regents Of The University Of Colorado	Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en)	2013-03-14	2016-03-15	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en)	2013-03-15	2014-09-18	Amarin Pharmaceuticals Ireland Limited	Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en)	2013-06-06	2021-04-06	Amarin Pharmaceuticals Ireland Limited	Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) *	2013-09-04	2015-03-05	Amarin Pharmaceuticals Ireland Limited	Methods of treating or preventing prostate cancer
US9585859B2 (en)	2013-10-10	2017-03-07	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10130603B2 (en)	2013-11-05	2018-11-20	Colgate-Palmolive Company	Methods and compositions for improving kidney function
ES2872449T3 (es) *	2013-12-04	2021-11-02	Nippon Suisan Kaisha Ltd	Aceite microbiano, procedimiento para fabricar aceite microbiano, aceite microbiano concentrado y procedimiento para fabricar aceite microbiano concentrado
MX375328B (es)	2014-06-04	2025-03-06	Ds Biopharma Ltd	Composiciones farmacéuticas que comprenden ácido dihomo-gamma-linolénico (dgla) y uso de las mismas
US10561631B2 (en)	2014-06-11	2020-02-18	Amarin Pharmaceuticals Ireland Limited	Methods of reducing RLP-C
WO2015195662A1 (fr)	2014-06-16	2015-12-23	Amarin Pharmaceuticals Ireland Limited	Procédés de réduction ou de prévention de l'oxydation des ldl petites et denses ou des acides gras polyinsaturés membranaires
US10406130B2 (en)	2016-03-15	2019-09-10	Amarin Pharmaceuticals Ireland Limited	Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10966951B2 (en)	2017-05-19	2021-04-06	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en)	2018-03-02	2021-07-13	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
MA50490A (fr)	2018-09-24	2020-09-02	Amarin Pharmaceuticals Ie Ltd	Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
CA3160676A1 (fr)	2019-11-12	2021-05-20	Amarin Pharmaceuticals Ireland Limited	Procedes de reduction du risque d'evenements cardiovasculaires chez un sujet souffrant d'une fibrillation auriculaire et/ou d'un flutter auriculaire
US20210315851A1 (en)	2020-04-03	2021-10-14	Afimmune Limited	Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
KR20220010415A (ko) *	2020-07-17	2022-01-25	대봉엘에스 주식회사	불포화 지방산을 특정 함량으로 포함하는 유지 조성물 및 이의 용도
US11986452B2 (en)	2021-04-21	2024-05-21	Amarin Pharmaceuticals Ireland Limited	Methods of reducing the risk of heart failure
WO2026030644A1 (fr) *	2024-07-31	2026-02-05	Caper Labs, Inc.	Thérapie à l'acide arachidonique pour le traitement de la neutropénie

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US551680A (en) *		1895-12-17		Water-tube steam-generator
US4526902A (en) *	1983-10-24	1985-07-02	Century Laboratories, Inc.	Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions
JPS60132916A (ja) *	1983-12-21	1985-07-16	Nisshin Oil Mills Ltd:The	血栓症予防食品または医薬品
US5252333A (en) *	1987-04-27	1993-10-12	Scotia Holdings Plc	Lithium salt-containing pharmaceutical compositions
GB8714772D0 (en) *	1987-06-24	1987-07-29	Efamol Ltd	Essential fatty acid compositions
US5198468A (en) *	1987-06-24	1993-03-30	Efamol Holdings Plc	Essential fatty acid composition
GB8813766D0 (en) *	1988-06-10	1988-07-13	Efamol Holdings	Essential fatty acid compositions
US5260067A (en) *	1988-11-16	1993-11-09	Xu Zheng	Cytotropic heterogeneous molecular lipids (CHML) and process for preparing the same
JPH04169524A (ja) *	1990-11-01	1992-06-17	Nissei Marine Kogyo Kk	血清脂質改善作用を有する組成物
US5658767A (en) *	1991-01-24	1997-08-19	Martek Corporation	Arachidonic acid and methods for the production and use thereof
GB9125602D0 (en) *	1991-12-02	1992-01-29	Efamol Holdings	Method of preventing reocclusion of arteries
JPH05163142A (ja) *	1991-12-17	1993-06-29	Tokiwa Yakuhin Kogyo Kk	肝障害の予防または治療用アラキドン酸含有組成物
US5223285A (en) *	1992-03-31	1993-06-29	Abbott Laboratories	Nutritional product for pulmonary patients
US5516801A (en) *	1992-08-21	1996-05-14	Scotia Holdings Plc	Fatty acid treatment for ectopic calcium deposition
GB9217781D0 (en) *	1992-08-21	1992-10-07	Efamol Holdings	Fatty acid treatment
GB9218064D0 (en) *	1992-08-25	1992-10-14	Efamol Holdings	Method for the safe intravenous administration of fatty acids
GB9224809D0 (en) *	1992-11-26	1993-01-13	Scotia Holdings Plc	Schizophrenia
GB9301446D0 (en) *	1993-01-26	1993-03-17	Scotia Holdings Plc	Internal radiation damage
GB9301629D0 (en) *	1993-01-27	1993-03-17	Scotia Holdings Plc	Formulations containing unsaturated fatty acids
CA2119000A1 (fr) *	1993-03-19	1994-09-20	David Frederick Horrobin	Formulation pour fumeurs
JPH06271464A (ja) *	1993-03-19	1994-09-27	Tokiwa Yakuhin Kogyo Kk	消化器系障害の予防または治療用アラキドン酸含有組成物
AUPM906594A0 (en) *	1994-10-26	1994-11-17	Peptide Technology Limited	Synthetic polyunsaturated fatty acid analogues
EP0711503A3 (fr) *	1994-11-14	1997-11-26	Scotia Holdings Plc	Lait fortifié avec GLA et/ou DGLA
GB9423625D0 (en) *	1994-11-23	1995-01-11	Scotia Holdings Plc	Fortified fruit juice
GB9617847D0 (en) *	1996-08-27	1996-10-09	Scotia Holdings Plc	Fatty acid treatment
ES2219871T3 (es) *	1997-02-21	2004-12-01	Abbott Laboratories	Procedimiento y composiciones que sirven para limitar la frecuencia de la enterocolitis necrotizante del recien nacido.
US5993221A (en) *	1997-05-01	1999-11-30	Beth Israel Deaconess Medical Center, Inc.	Dietary formulation comprising arachidonic acid and methods of use
CN1212867A (zh) *	1997-09-29	1999-04-07	宋凤亭	防治心脑血管疾病的组合物
DE19757414A1 (de) *	1997-12-23	1999-07-01	Nutricia Nv	Fettmischung
CN1326344A (zh)	1998-10-15	2001-12-12	Dsm公司	Pufa增补剂
SE9900941D0 (sv) *	1998-12-23	1999-03-16	Nomet Management Serv Bv	Novel retinoic acid derivatives and their use
GB9901809D0 (en)	1999-01-27	1999-03-17	Scarista Limited	Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes

2000
- 2000-06-29 GB GBGB0016045.7A patent/GB0016045D0/en not_active Ceased
2001
- 2001-06-20 DE DE60116625T patent/DE60116625T2/de not_active Expired - Lifetime
- 2001-06-20 HR HR20030035A patent/HRP20030035A2/hr not_active Application Discontinuation
- 2001-06-20 BR BR0112073-5A patent/BR0112073A/pt not_active Application Discontinuation
- 2001-06-20 PT PT01940775T patent/PT1296670E/pt unknown
- 2001-06-20 UA UA20021210705A patent/UA76108C2/uk unknown
- 2001-06-20 RU RU2002133098/15A patent/RU2276975C2/ru not_active IP Right Cessation
- 2001-06-20 AT AT01940775T patent/ATE315388T1/de active
- 2001-06-20 HU HU0301107A patent/HUP0301107A2/hu unknown
- 2001-06-20 NZ NZ522916A patent/NZ522916A/en unknown
- 2001-06-20 IL IL15345801A patent/IL153458A0/xx not_active IP Right Cessation
- 2001-06-20 AU AU2001274276A patent/AU2001274276B2/en not_active Ceased
- 2001-06-20 SK SK1816-2002A patent/SK287209B6/sk not_active IP Right Cessation
- 2001-06-20 CZ CZ20024173A patent/CZ20024173A3/cs unknown
- 2001-06-20 PL PL01359185A patent/PL359185A1/xx not_active Application Discontinuation
- 2001-06-20 MX MXPA02012689A patent/MXPA02012689A/es active IP Right Grant
- 2001-06-20 JP JP2002506727A patent/JP2004501969A/ja active Pending
- 2001-06-20 KR KR1020027017649A patent/KR20030016306A/ko not_active Ceased
- 2001-06-20 WO PCT/GB2001/002717 patent/WO2002002105A1/fr not_active Ceased
- 2001-06-20 EE EEP200200718A patent/EE05148B1/xx not_active IP Right Cessation
- 2001-06-20 YU YU99602A patent/YU99602A/sh unknown
- 2001-06-20 AU AU7427601A patent/AU7427601A/xx active Pending
- 2001-06-20 CA CA002411368A patent/CA2411368C/fr not_active Expired - Fee Related
- 2001-06-20 DK DK01940775T patent/DK1296670T3/da active
- 2001-06-20 CN CNB01811931XA patent/CN100469363C/zh not_active Expired - Fee Related
- 2001-06-20 ES ES01940775T patent/ES2256250T3/es not_active Expired - Lifetime
- 2001-06-20 EP EP01940775A patent/EP1296670B1/fr not_active Expired - Lifetime
- 2001-06-21 MY MYPI20012947A patent/MY117830A/en unknown
- 2001-06-29 TW TW090116201A patent/TWI285549B/zh not_active IP Right Cessation
- 2001-06-29 US US09/893,473 patent/US6479544B1/en not_active Expired - Lifetime
2002
- 2002-11-29 IS IS6644A patent/IS2226B/is unknown
- 2002-12-18 NO NO20026093A patent/NO329868B1/no not_active IP Right Cessation
2003
- 2003-01-08 ZA ZA200300198A patent/ZA200300198B/en unknown

Also Published As

Publication number	Publication date
HUP0301107A2 (hu)	2003-08-28
CA2411368C (fr)	2009-11-17
EP1296670B1 (fr)	2006-01-11
MY117830A (en)	2004-08-30
PL359185A1 (en)	2004-08-23
NZ522916A (en)	2004-03-26
CZ20024173A3 (cs)	2003-05-14
CN1438884A (zh)	2003-08-27
GB0016045D0 (en)	2000-08-23
DK1296670T3 (da)	2006-05-08
HK1050486A1 (en)	2003-06-27
CN100469363C (zh)	2009-03-18
KR20030016306A (ko)	2003-02-26
EE200200718A (et)	2004-08-16
SK287209B6 (sk)	2010-03-08
EP1296670A1 (fr)	2003-04-02
DE60116625D1 (de)	2006-04-06
SK18162002A3 (sk)	2003-08-05
EE05148B1 (et)	2009-04-15
JP2004501969A (ja)	2004-01-22
TWI285549B (en)	2007-08-21
PT1296670E (pt)	2006-05-31
BR0112073A (pt)	2003-05-20
AU7427601A (en)	2002-01-14
ATE315388T1 (de)	2006-02-15
IS2226B (is)	2007-04-15
YU99602A (sh)	2006-05-25
ES2256250T3 (es)	2006-07-16
HRP20030035A2 (en)	2003-04-30
DE60116625T2 (de)	2006-12-14
NO20026093L (no)	2002-12-18
CA2411368A1 (fr)	2002-01-10
WO2002002105A1 (fr)	2002-01-10
NO20026093D0 (no)	2002-12-18
ZA200300198B (en)	2004-01-26
IS6644A (is)	2002-11-29
US6479544B1 (en)	2002-11-12
NO329868B1 (no)	2011-01-17
MXPA02012689A (es)	2004-04-20
RU2276975C2 (ru)	2006-05-27
IL153458A0 (en)	2003-07-06
AU2001274276B2 (en)	2006-03-30

Publication	Publication Date	Title
RU2276975C2 (ru)	2006-05-27	Терапевтические комбинации жирных кислот
AU2001274276A1 (en)	2002-04-11	Therapeutic combinations of fatty acids
US5589508A (en)	1996-12-31	Use of an emulsion to prepare an intravensously administered medicament for treating skin diseases
AU618814B2 (en)	1992-01-09	Essential fatty acid compositions
US5198468A (en)	1993-03-30	Essential fatty acid composition
SK14502003A3 (en)	2004-10-05	Coenzyme Q and eicosapentaenoic acid
JP2005535733A (ja)	2005-11-24	ドライアイ、マイボーム腺炎及び口内乾燥症の治療用ｅｐａ及びｄｈａ富化オメガ−３補給剤
JPH06157303A (ja)	1994-06-03	脂肪酸治療
ZA200308417B (en)	2004-05-24	Potentiation of therapeutic effects of fatty acids.
US20200085774A1 (en)	2020-03-19	Omega-3 Fatty Acid Composition for Preventing and/or Treating Cachexia
CA1334002C (fr)	1995-01-17	Compositions a base d'acides gras essentiels et methodes de modulation de la concentration des prostaglandines chez les mammiferes
JP2941787B2 (ja)	1999-08-30	多価不飽和脂肪酸を含有する医薬組成物および健康食品
JP3947322B2 (ja)	2007-07-18	多価不飽和脂肪酸を含有する医薬組成物および健康食品
HK1050486B (en)	2006-05-26	Therapeutic combinations of fatty acids